3
H index
0
i10 index
12
Citations
Christopher James Sampson : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 8 Articles 10 Papers RESEARCH ACTIVITY:
EXPERT IN:
MORE DETAILS IN: ABOUT THIS REPORT:
|
11 years (2013 - 2024). 
Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Christopher James Sampson. | Is cited by:
| Cites to:
|
Main data
Where Christopher James Sampson has published?
| Journals with more than one article published | # docs |
|---|---|
| PharmacoEconomics - Open | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| MPRA Paper / University Library of Munich, Germany | 3 |
| Contract Research / Office of Health Economics | 3 |
| Grant-Funded Research / Office of Health Economics | 2 |
| Briefing / Office of Health Economics | 2 |
Recent works citing Christopher James Sampson (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2024 | Optimal intertemporal curative drug expenses: The case of hepatitis C in France. (2024). Magnac, Thierry ; Dubois, Pierre. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629624000067. Full description at Econpapers || Download paper |
Works by Christopher James Sampson:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2024 | Marginal cost per QALY estimates: What are they good for? In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing. [Citation analysis] | paper | 3 |
| 2021 | How is Quality of Life Measured for Health Technology Assessments? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| In: . [Full Text][Citation analysis] | paper | 0 | |
| In: . [Full Text][Citation analysis] | paper | 0 | |
| In: . [Full Text][Citation analysis] | paper | 0 | |
| In: . [Full Text][Citation analysis] | paper | 1 | |
| In: . [Full Text][Citation analysis] | paper | 0 | |
| 2013 | Cost implications of treatment non-completion in a forensic personality disorder service In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
| 2013 | Happy and healthy: a joint model of health and life satisfaction In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
| 2013 | The relationship between individual risk and cost-effectiveness in screening interventions In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
| 2021 | Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. In: Medical Decision Making. [Full Text][Citation analysis] | article | 1 |
| 2022 | Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2013 | Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776 In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2019 | Transparency in Decision Modelling: What, Why, Who and How? In: PharmacoEconomics. [Full Text][Citation analysis] | article | 3 |
| 2017 | Model Registration: A Call to Action In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 4 |
| 2022 | NICE and the EQ-5D-5L: Ten Years Trouble In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2024 | Is anchoring at ‘dead’ a theoretical requirement for health state valuation? In: Health Economics. [Full Text][Citation analysis] | article | 0 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team